Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model

Cancer Research

Volumn 63, Issue 18, 2003, Pages 5859-5865

  McAlhany, Stephanie J ^a   Ressler, Steven J ^a   Larsen, Melinda ^a,b   Tuxhorn, Jennifer A ^a,c   Yang, Feng ^a   Dang, Truong D ^a   Rowley, David R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c WYLE LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIFEPRISTONE; PROTEIN; PROTEIN PS20; SCLEROPROTEIN; SERINE PROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; WHEY ACIDIC PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL INTERACTION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MYOFIBROBLAST; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; RNA SYNTHESIS; STROMA; STROMA CELL; VASCULAR SMOOTH MUSCLE; WFDC1 GENE; XENOGRAFT;

3T3 CELLS; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; MUSCLE, SMOOTH, VASCULAR; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEINS; RNA, MESSENGER; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HETEROLOGOUS;

EID: 0141619325     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Tuxhorn, J. A., Ayala, G. E., Smith, M. J., Smith, V. C., Dang, T. D., and Rowley, D. R. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res., 8: 2912-2923, 2002.
2. Tuxhorn, J. A., McAlhany, S. J., Dang, T. D., Ayala, G. E., and Rowley, D. R. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res., 62: 3298-3307, 2002.
3. Tuxhorn, J. A., McAlhany, S. J., Yang, F., Dang, T. D., and Rowley, D. R. Inhibition of transforming growth factor-β activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res., 62: 6021-6025, 2002.
4. Larsen, M., Ressler, S. J., Lu, B., Gerdes, M. J., McBride, L., Dang, T. D., and Rowley, D. R. Molecular cloning and expression of ps20 growth inhibitor. A novel WAP-type "four-disulfide core" domain protein expressed in smooth muscle. J. Biol. Chem., 273: 4574-4584, 1998.
5. Rowley, D. R., Dang, T. D., Larsen, M., Gerdes, M. J., McBride, L., and Lu, B. Purification of a novel protein (ps20) from urogenital sinus mesenchymal cells with growth inhibitory properties in vitro. J. Biol. Chem., 270: 22058-22065, 1995.
6. Rowley, D. R. Characterization of a fetal urogenital sinus mesenchymal cell line U4F: secretion of a negative growth regulatory activity. In Vitro Cell Dev. Biol., 28A: 29-38, 1992.
7. Larsen, M., Ressler, S. J., Gerdes, M. J., Lu, B., Byron, M., Lawrence, J. B., and Rowley, D. R. The WFDC1 gene encoding ps20 localizes to 16q24, a region of LOH in multiple cancers. Mamm. Genome, 11: 767-773, 2000.
8. Hennighausen, L. G., and Sippel, A. E. Mouse whey acidic protein is a novel member of the family of 'four-disulfide core' proteins. Nucleic Acids Res., 10: 2677-2684, 1982.
9. Thompson, R. C., and Ohlsson, K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc. Natl. Acad. Sci. USA, 83: 6692-6696, 1986.
10. Wiedow, O., Schroder, J. M., Gregory, H., Young, J. A., and Christophers, E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem., 265: 14791-14795, 1990.
11. Schalkwijk, J., Wiedow, O., and Hirose, S. The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem. J., 340: 569-577, 1999.
12. Barolet, A. W., Nili, N., Cheema, A., Robinson, R., Natarajan, M. K., O'Blenes, S., Li, J., Eskandarian, M. R., Sparkes, J., Rabinovitch, M., and Strauss, B. H. Arterial elastase activity after balloon angioplasty and effects of elafin, an elastase inhibitor. Arterioscler. Thromb Vasc. Biol., 21: 1269-1274, 2001.
13. Zaidi, S. H., You, X. M., Ciura, S., Husain, M., and Rabinovitch, M. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation, 105: 516-521, 2002.
14. Ashcroft, G. S., Lei, K., Jin, W., Longenecker, G., Kulkarni, A. B., Greenwell-Wild, T., Hale-Donze, H., McGrady, G., Song, X. Y., and Wahl, S. M. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat. Med., 6: 1147-1153, 2000.
15. Wheeler, T. M., and Lebovitz, R. M. Fresh tissue harvest for research from prostatectomy specimens. Prostate, 25: 274-279, 1994.
16. Hirschi, K. K., Rohovsky, S. A., and D'Amore, P. A. PDGF, TGF-β, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J. Cell Biol., 141: 805-814, 1998.
17. Gerdes, M. J., Dang, T. D., Lu, B., Larsen, M., McBride, L., and Rowley, D. R. Androgen-regulated proliferation and gene transcription in a prostate smooth muscle cell line (PS-1). Endocrinology, 137: 864-872, 1996.
18. Abruzzese, R. V., Godin, D., Mehta, V., Perrard, J. L., French, M., Nelson, W., Howell, G., Coleman, M., O'Malley, B. W., and Nordstrom, J. L. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. Mol. Ther., 2: 276-287, 2000.
19. Burcin, M. M., Schiedner, G., Kochanek, S., Tsai, S. Y., and O'Malley, B. W. Adenovirus-mediated regulable target gene expression in vivo. Proc. Natl. Acad. Sci. USA. 96: 355-360, 1999.
20. Janik, P., Briand, P., and Hartmann, N. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res., 35: 3698-3704, 1975.
21. Fox, S. B. Microscopic assessment of angiogenesis in tumors. In: J. C. Murray (ed.), Methods in Molecular Medicine: Angiogenesis Protocols, Vol. 46, pp. 29-46. Totowa, NJ: Humana Press Inc., 2001.
22. Jin, F. Y., Nathan, C., Radzioch, D., and Ding, A. Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell, 88: 417-426, 1997.
23. Gray, L. R., Alexander, A. L., and Shugars, D. C. Construction, non-denaturing affinity purification, and characterization of baculovirally expressed human secretory leukocyte protease inhibitor. Protein Expr. Purif. 26: 179-186, 2002.
24. Liekens, S., De Clercq, E., and Neyts, J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol., 61: 253-270, 2001.
25. Thompson, K., and Rabinovitch, M. Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor. J. Cell Physiol., 166: 495-505, 1996.
26. Tuxhorn, J. A., Ayala, G. E., and Rowley, D. R. Reactive stroma in prostate cancer progression. J. Urol., 166: 2472-2483, 2001.
27. Brawer, M. K., Deering, R. E., Brown, M., Preston, S. D., and Bigler, S. A. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer (Phila.), 73: 678-687, 1994.
28. Pedersen, H., Brunner, N., Francis, D., Osterlind, K., Ronne, E., Hansen, H. H., Dano, K., and Grondahl-Hansen, J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 54: 4671-4675, 1994.
29. Pedersen, H., Grondahl-Hansen, J., Francis, D., Osterlind, K., Hansen, H. H., Dano, K., and Brunner, N. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res., 54: 120-123, 1994.
30. Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, T. L., Brunner, N., Dano, K., Fusenig, N. E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., Carmeliet, P., Foidart, J. M., and Noel, A. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J. Cell Biol., 152: 777-784, 2001.
31. Bajou, K., Noel, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., and Foidart, J. M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med., 4: 923-928, 1998.
32. Wen, W., Moses, M. A., Wiederschain, D., Arbiser, J. L., and Folkman, J. The generation of endostatin is mediated by elastase. Cancer Res., 59: 6052-6056, 1999.
33. Gee, M. S., Procopio, W. N., Makonnen, S., Feldman, M. D., Yeilding, N. M., and Lee, W. M. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am. J. Pathol., 162: 183-193, 2003.
34. Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., and Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Investig., 103: 159-165, 1999.
35. Hirschi, K. K., and D'Amore, P. A. Pericytes in the microvasculature. Cardiovasc. Res., 32: 687-698, 1996.
36. Sinha, S., and Frishman, W. H. Matrix metalloproteinases and abdominal aortic aneurysms: a potential therapeutic target. J. Clin. Pharmacol., 38: 1077-1088, 1998.
37. Thompson, R. W., and Parks, W. C. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann. N. Y. Acad. Sci., 800: I57-I74, 1996.